Reynders McVeigh Capital Management LLC Has $1.69 Million Stake in CRISPR Therapeutics AG $CRSP

Reynders McVeigh Capital Management LLC lowered its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) by 74.8% in the second quarter, Holdings Channel reports. The firm owned 31,065 shares of the company’s stock after selling 92,373 shares during the quarter. Reynders McVeigh Capital Management LLC’s holdings in CRISPR Therapeutics were worth $1,694,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Norges Bank bought a new stake in CRISPR Therapeutics during the 4th quarter worth about $25,706,000. Capital International Investors grew its holdings in shares of CRISPR Therapeutics by 4.3% in the 4th quarter. Capital International Investors now owns 5,892,745 shares of the company’s stock valued at $309,016,000 after acquiring an additional 243,487 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its position in shares of CRISPR Therapeutics by 2,346.7% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 230,305 shares of the company’s stock valued at $12,077,000 after acquiring an additional 220,892 shares during the last quarter. Affinity Asset Advisors LLC acquired a new stake in shares of CRISPR Therapeutics in the first quarter valued at about $7,136,000. Finally, KBC Group NV raised its holdings in CRISPR Therapeutics by 3,999.9% during the first quarter. KBC Group NV now owns 116,847 shares of the company’s stock worth $5,558,000 after acquiring an additional 113,997 shares in the last quarter. 69.20% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics Stock Performance

NASDAQ CRSP traded down $1.13 during trading on Tuesday, reaching $51.83. 1,248,127 shares of the company’s stock were exchanged, compared to its average volume of 1,739,759. The company has a debt-to-equity ratio of 0.34, a current ratio of 17.85 and a quick ratio of 17.85. The business has a 50 day moving average price of $53.31 and a 200-day moving average price of $52.91. The stock has a market capitalization of $5.01 billion, a P/E ratio of -10.89 and a beta of 1.76. CRISPR Therapeutics AG has a fifty-two week low of $44.12 and a fifty-two week high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Tuesday, June 30th. The company reported ($0.94) earnings per share (EPS) for the quarter. CRISPR Therapeutics had a negative net margin of 3,368.72% and a negative return on equity of 24.39%. The business had revenue of $10.18 million during the quarter. Sell-side analysts forecast that CRISPR Therapeutics AG will post -4.47 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have weighed in on CRSP shares. Needham & Company LLC restated a “buy” rating and issued a $82.00 price target on shares of CRISPR Therapeutics in a research note on Monday, August 31st. Wall Street Zen raised shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Citizens Jmp restated a “market outperform” rating and set a $80.00 target price on shares of CRISPR Therapeutics in a report on Monday, August 31st. Citigroup reaffirmed a “market outperform” rating on shares of CRISPR Therapeutics in a research report on Tuesday, August 25th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of CRISPR Therapeutics in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, CRISPR Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $68.06.

CRISPR Therapeutics Profile

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing gene-editing medicines using CRISPR/Cas9 technology. The company’s programs are designed to modify disease-associated genes in human cells, with the goal of treating serious conditions across hematology, oncology, autoimmune disease and regenerative medicine.

Its most advanced product is Casgevy (exa-cel), an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals. Casgevy uses CRISPR/Cas9 gene editing to modify a patient’s blood stem cells and is approved in several markets for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia.